Author + information
- Tushar A. Tuliani,
- Maithili Shenoy,
- Abhishek Deshmukh,
- Muhammad Janjua,
- Sadip Pant,
- Kaustubh Dabhadkar,
- Apurva Badheka,
- Diane Levine and
- Luis Afonso
Subclinical hypothyroidism (SCH) has been linked to adverse cardiovascular outcomes (CVO). We sought to explore if SCH alters biomarkers which could explain its effects on long term CVO.
We queried the NHANES-III (n=7499). We excluded individuals with age <40 years, TSH levels ≥20 and ≤0.35mIU/L. We defined SCH as TSH levels between 5-19.99 mlU/L and serum T4 levels between 5-12 µg/dl. TSH levels between 0.36-4.99 were considered euthyroid. Microalbuminuria (MIA) was defined as urine albumin to creatinine ratio of 17-250 mg/g in men and 25-355 mg/g in women. Serum homocysteine and insulin were log transformed. We used Chi-squared test and adjusted wald's test for categorical and continuos variables respectively. Survey weights were used to account for complex survey design.
Prevalence of African American ethnicity was 9.6% versus 3.1% (p-value-<0.001), male sex 48.4% versus 28.2% (p-value-<0.001), mean age 56.4 versus 62 years (p-value-<0.001), diabetes 9.2% versus 9.6% (p-value-0.9), hypertension 37.4% versus 49.2% (p-value<0.001) in individuals with euthyroid (n=7115) and SCH group (n=384) respectively. MIA was the only CV biomarker that was significantly different between the two groups.
MIA is a strong marker of CV risk and could explain the adverse effects of SCH on CV outcomes. MIA is amenable to treatment and further clinical trials are warranted to study effects of early medical treatment in patients with SCH on CVO.
Poster Sessions, Expo North
Saturday, March 09, 2013, 3:45 p.m.-4:30 p.m.
Session Title: Prevention: Risk Factors, from Tooth Loss to Resistin
Abstract Category: 24. Prevention: Clinical
Presentation Number: 1147-18
- 2013 American College of Cardiology Foundation